Cannabis study aims to unlock HIV immune secrets
NCT ID NCT06034314
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how cannabis (specifically the drug Dronabinol) changes the immune system and genes in people with HIV. Researchers will take blood samples before and after giving Dronabinol to 160 participants. The goal is to understand these changes better, which could help shape public health policies and lead to new treatments for cannabis-related disorders.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2023
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
PWH Inclusion Criteria: * Current or past Cannabis use. * HIV-positive on antiretroviral therapy. * Meet criteria of viral suppression (viral load less than approximately 400 copies/ml). * Good physical and mental health as determined by history, the SCID, collateral information, physical and laboratory examinations, ECG, and vital signs. * Women of Childbearing Potential: Must agree to use or have their partner use one acceptable method of birth control throughout the study, at the discretion of the principal investigator. PWoH Inclusion Criteria: * Current or past Cannabis use. * Good physical and mental health as determined by history, the SCID, collateral information, physical and laboratory examinations, ECG, and vital signs. * Women of Childbearing Potential: Must agree to use or have their partner use one acceptable method of birth control throughout the study, at the discretion of the principal investigator. Exclusion Criteria: * Cannabis naïve individuals. * Under the age of 18 years. * Unable to provide written informed consent. * Unable to read or write in English. * Unable to tolerate the effects of smoking approximately half a joint of cannabis (or equivalent), at the discretion of the principal investigator. * Major or clinically unstable medical conditions (e.g., myocardial infarction, hypertension, clinically significant head injury or loss of consciousness). * IQ less than 80. * Diagnosis of psychosis confirmed by SCID. * Other medical, psychiatric, or psychosocial history that is deemed unsuitable for participation in study per PI. * Has donated blood within the last 8 weeks. * Sesame oil allergy. * Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants (e.g., barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, muscle relaxants). * Patients with cardiac disorders or concomitant use of other drugs that are associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). * Patients with a history of seizures, including those receiving anti-epileptic medication or with other factors that can lower the seizure threshold.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Connecticut Mental Health Center
New Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can 'Queen Mothers' bring HIV testing to the doorstep?
- Scientists map HIV's hiding spots in early infection
- Can local clinics keep more people with HIV in care?
- Can a phone call keep HIV-Positive mothers and babies on track?
- Can a phone app and a health worker ease depression in rural HIV care?
- Can a diabetes and Weight-Loss drug help break cocaine addiction?